Peptides
Ipamorelin
A research compound with important gaps in safety information across administration routes.
Limited / route-specific evidence
Also known as: ipamorelin acetate
Practical use
Applying the explained evidence
- Where it fits
- A research compound with important gaps in safety information across administration routes.
- Put the information into practice
- Results from one route or clinical population should not be assumed to apply to another.
- Check what was actually tested
- Match the exact molecule, formulation and study setting to the claim. A result for a related peptide, a cell model or an animal model does not establish the same result for a marketed human-use product.
- Keep this limit in view
- Selectivity describes particular pharmacological responses. It does not establish purity, long-term safety or safety across routes and patient populations.
Overview
FDA’s review highlights gaps in safety information for certain injectable routes.
Risks and limitations
Serious events, including deaths, were reported in an intravenous gastric-motility study. This does not establish causality or quantify risk for every route.
How to read this
Results from one route or clinical population should not be assumed to apply to another.
Research explained
Postoperative bowel-function trial
Who was studied
117 enrolled adults after bowel resection; 114 in safety and modified intention-to-treat analyses. Intravenous treatment, up to seven days.
What was found
Median time to a tolerated solid meal was 25.3 hours versus 32.6 hours with placebo; the difference was not statistically significant (p=0.15). The trial did not demonstrate efficacy on its key or secondary analyses.
What it cannot establish
This small hospital study concerns recovery after surgery. It cannot establish bodybuilding, fat-loss or long-term benefits, or the safety of a different administration route.
Read the original studyWhy it is called a secretagogue
Ipamorelin is a ghrelin-receptor agonist: it activates a receptor involved in GH release and gastrointestinal physiology. That mechanism helps explain why a bowel-function trial was conducted. It does not mean the compound is equivalent to injected GH, a GHRH analog or an androgen.
Supporting sourceReconciling the trial with the FDA warning
The published abstract describes tolerability in its postoperative trial. FDA separately highlights serious events, including death, reported during intravenous gastric-motility research and insufficient information for certain other injectable routes. These statements require context: an event occurring during a study does not establish causation, while a small tolerability study does not establish broad safety.
Supporting sourceClaims versus findings
Unsupported inference
“Selective means free of side effects.”
Selectivity describes particular pharmacological responses. It does not establish purity, long-term safety or safety across routes and patient populations.
Check the evidenceCommon questions
Does this trial show that it improves gym recovery?
No. Its main outcome was tolerance of a solid meal after bowel surgery, not recovery from resistance training.
SourceSources
Postoperative bowel-function trial
Sources checked 2026-09-28.
General education; not a personal treatment plan.